MLV: Galectin Therapeutics Stock Rating Reaffirmed by MLV & Co. (GALT)

MLV & Co. reissued their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a report published onWednesday, AnalystRatingsNetwork.com reports. MLV & Co. currently has a $16.00 price target on the stock. Galectin Therapeutics (NASDAQ:GALT) opened at 2.38 on Wednesday. Galectin Therapeutics has a 12 month low of $1.91 and a 12 month high of [...]